- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05461924
The Long Term Outcomes After Pull-through of Long Segment Hirschsprung Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.
The long-term outcome would be indicated by bowel function SCORE.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Weibing Tang, Dr
- Phone Number: 025-83117354 8613851683700
- Email: twbcn@163.com
Study Contact Backup
- Name: Changgui Lu, Dr
- Phone Number: 025-83117354 8613770848448
- Email: luchanggui1984@163.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Children's Hospital of Nanjing Medical University
-
Contact:
- Lu Changgui, Dr
- Phone Number: 8613770848448
- Email: luchanggui1984@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
patients with with rectosigmoid and long-segment Hirschsprung disease after operation.
The follow-up age must more than 3 years old.
Description
Inclusion Criteria:
Clinical diagnosis of Hirschsprung disease Must be performed with the operation of pull-through Must be followed up more than 3 years
Exclusion Criteria:
Clinical diagnosis of Down syndrome Clinical diagnosis of tolal colonic Hirschsprung disease Clinical diagnosis of degestive malformation except Hirschsprung disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
long-segment HSCR
Aganglionosis of non-rectosigmoid HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum
|
questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
|
|
rectosigmoid HSCR
Aganglionosis confined to the rectosigmoid
|
questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bowel function score
Time Frame: through study completion, an average of 5 year
|
Bowel function was evaluated by the BFS (20 points), which was approved by Rintala in 1995 ; patients with a score > 18 were considered to have normal bowel habits.
|
through study completion, an average of 5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hirschspurng disease associated entrocolitis(HAEC)
Time Frame: through study completion, an average of 5 year
|
The guidelines for the diagnosis and management of HAEC were defined by the American Pediatric Surgical Association in 2017
|
through study completion, an average of 5 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Changgui Lu, Dr, Department of pediatric surgery of Children's hospital of Nanjing medical unverisity
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NanjingCH-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
Peking Union Medical College HospitalInstitute of Process Engineering, Chinese Academy of SciencesNot yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota TransplantationChina
-
Hamilton Health Sciences CorporationNot yet recruitingConstipation | Constipation - Functional | Constipation AggravatedCanada
-
Singapore Institute of TechnologyNot yet recruitingConstipation | Diet Modification | Constipation-predominant Irritable Bowel Syndrome | Diet Therapy | Constipation - Functional | Constipation Chronic Idiopathic | Constipation, Signs and Symptoms, Digestive | Dietary Fiber | Dietary Fibers | Constipation Predominant Irritable Bowel Syndrome | Dietary and... and other conditionsSingapore
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Peking Union Medical College HospitalRecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)China
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Hong Kong Metropolitan UniversityNot yet recruitingConstipation | Constipation Drug Induced | Psychiatric Drug Induced ConstipationHong Kong
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
Hong Kong Metropolitan UniversityHospital Authority, Hong KongRecruitingConstipation | Constipation Drug Induced | Psychiatric Drug Induced ConstipationHong Kong
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
Clinical Trials on questionnaire survey
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Mbarara University of Science and...Completed
-
M.D. Anderson Cancer CenterCompleted
-
Frederiksberg University HospitalTerminated
-
First Affiliated Hospital of Wenzhou Medical UniversityQilu Hospital of Shandong University; Eastern Hepatobiliary Surgery Hospital; The First Affiliated Hospital of Zhejiang Chinese Medical UniversityEnrolling by invitationEfficacy | Liver Cancer | Adverse Event | Microbiota | PrognosisChina
-
Second Affiliated Hospital, School of Medicine,...Enrolling by invitation
-
Samsung Medical CenterActive, not recruitingOccupational Diseases | Emergency DepartmentsKorea, Republic of
-
Stanford UniversityCompletedBreast CancerUnited States
-
Peking University Third HospitalCompleted
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)UnknownGlioma | Brain TumorUnited States, Finland, Sweden, Denmark, Israel, United Kingdom